clinical trial · NCT04993677
A Study of SEA-CD40 Given With Other Drugs in Cancers
MelanomaCarcinoma, Non-Small- Cell LungSEA-CD40pembrolizumab (KEYTRUDA®)pemetrexedcarboplatin
brief summary
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.
started
Oct 6, 2021
primary completion
Jan 3, 2024
completion
Nov 25, 2024
last updated
May 11, 2025
official title
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol